Cadrenal Therapeutics (CVKD) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.09, +12.37% vs the prior close of $0.97.
- Volume 169.78K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CVKD jumps 12.4% to $1.09. Closed at $1.09, +12.37% vs the prior close of $0.97. Day range $0.96–$1.12, opened at $0.99.
CVKD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CVKD jumps 12.4% to $1.09
- Closed at $1.09, +12.37% vs the prior close of $0.97. Day range $0.96–$1.12, opened at $0.99.
- Volume was 169.78K shares, 0.3x its 50-day average of 583.66K — lighter than usual.
- Price is -16.6% vs its 50-day average ($1.31) and -74.5% vs its 200-day average ($4.28).
- 52-week range $0.82–$14.21; today's close sits at 2% of that range, 92.3% below the 52-week high.
Oct 15, 2026 — CVKD slides 4.9% to $0.97
- Closed at $0.97, -4.90% vs the prior close of $1.02. Day range $0.96–$1.03, opened at $0.99.
- Volume was 104.20K shares, 0.2x its 50-day average of 582.23K — lighter than usual.
- Price is -26.7% vs its 50-day average ($1.32) and -77.5% vs its 200-day average ($4.31).
- 52-week range $0.82–$14.35; today's close sits at 1% of that range, 93.2% below the 52-week high.
Oct 14, 2026 — CVKD rises 2.3% to $1.02
- Closed at $1.02, +2.31% vs the prior close of $1.00. Day range $0.92–$1.10, opened at $0.93.
- Volume was 344.30K shares, 0.6x its 50-day average of 576.16K — lighter than usual.
- Price is -24.0% vs its 50-day average ($1.34) and -76.5% vs its 200-day average ($4.34).
- 52-week range $0.82–$14.35; today's close sits at 2% of that range, 92.9% below the 52-week high.
Oct 13, 2026 — CVKD jumps 14.3% to $1.00
- Closed at $1.00, +14.33% vs the prior close of $0.87. Day range $0.87–$1.06, opened at $0.89.
- Volume was 376.40K shares, 0.7x its 50-day average of 569.45K.
- Price is -26.9% vs its 50-day average ($1.36) and -77.2% vs its 200-day average ($4.37).
- 52-week range $0.82–$14.50; today's close sits at 1% of that range, 93.1% below the 52-week high.
Oct 12, 2026 — CVKD slides 4.2% to $0.87, a 52-week low, 4 down days in a row
- Closed at $0.87, -4.18% vs the prior close of $0.91. Day range $0.82–$0.92, opened at $0.92.
- Volume was 111.40K shares, 0.2x its 50-day average of 567.52K — lighter than usual.
- Price is -36.9% vs its 50-day average ($1.38) and -80.2% vs its 200-day average ($4.40).
- 52-week range $0.82–$14.50; today's close sits at 0% of that range, 94.0% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — CVKD dips 2.2% to $0.91, a 52-week low, 3 down days in a row
- Closed at $0.91, -2.15% vs the prior close of $0.93. Day range $0.90–$0.97, opened at $0.97.
- Volume was 82.40K shares, 0.1x its 50-day average of 566.23K — lighter than usual.
- Price is -35.2% vs its 50-day average ($1.41) and -79.5% vs its 200-day average ($4.44).
- 52-week range $0.85–$14.50; today's close sits at 0% of that range, 93.7% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — CVKD slides 4.3% to $0.93, a 52-week low
- Closed at $0.93, -4.32% vs the prior close of $0.97. Day range $0.87–$0.99, opened at $0.99.
- Volume was 311.20K shares, 0.6x its 50-day average of 560.27K — lighter than usual.
- Price is -34.9% vs its 50-day average ($1.43) and -79.2% vs its 200-day average ($4.47).
- 52-week range $0.85–$14.50; today's close sits at 1% of that range, 93.6% below the 52-week high.
Oct 7, 2026 — CVKD dips 1.8% to $0.97 on 3.4x normal volume
- Closed at $0.97, -1.82% vs the prior close of $0.99. Day range $0.92–$1.07, opened at $1.01.
- Volume was 1.78M shares, 3.4x its 50-day average of 525.29K — unusually heavy trading.
- Price is -32.9% vs its 50-day average ($1.45) and -78.4% vs its 200-day average ($4.50).
- 52-week range $0.85–$14.50; today's close sits at 1% of that range, 93.3% below the 52-week high.
- SEC filings that day: 8-K.
Oct 6, 2026 — CVKD jumps 4.7% to $0.99
- Closed at $0.99, +4.65% vs the prior close of $0.95. Day range $0.90–$1.05, opened at $0.94.
- Volume was 98.00K shares, 0.2x its 50-day average of 524.75K — lighter than usual.
- Price is -32.7% vs its 50-day average ($1.47) and -78.2% vs its 200-day average ($4.53).
- 52-week range $0.85–$14.50; today's close sits at 1% of that range, 93.2% below the 52-week high.
Oct 5, 2026 — CVKD rises 0.6% to $0.95
- Closed at $0.95, +0.64% vs the prior close of $0.94. Day range $0.94–$1.00, opened at $0.97.
- Volume was 63.00K shares, 0.1x its 50-day average of 525.09K — lighter than usual.
- Price is -36.6% vs its 50-day average ($1.49) and -79.3% vs its 200-day average ($4.57).
- 52-week range $0.85–$14.64; today's close sits at 1% of that range, 93.5% below the 52-week high.
Oct 2, 2026 — CVKD slides 3.1% to $0.94, a 52-week low, 7 down days in a row
- Closed at $0.94, -3.09% vs the prior close of $0.97. Day range $0.85–$1.00, opened at $0.98.
- Volume was 149.60K shares, 0.3x its 50-day average of 523.29K — lighter than usual.
- Price is -37.9% vs its 50-day average ($1.51) and -79.6% vs its 200-day average ($4.60).
- 52-week range $0.85–$14.64; today's close sits at 1% of that range, 93.6% below the 52-week high.
- That makes 7 straight losses.
CVKD latest news & SEC filings
Every SEC filing by or about CVKD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 8, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Oct 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Sep 3, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.32M (prior year -$3.67M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.14 (prior year -$1.87) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 3, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Things to know before you trade CVKD
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 31, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.34% (largest 17.9%). That is a volatile stock.
- Liquidity: about 229.48K shares (≈$250.14K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.09 vs a range of $0.82–$14.21 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Quang X Pham sold 7,400 shares on Jun 29, 2026.
- Latest filings: 8-K Oct 7, 2026; 8-K Sep 29, 2026; 8-K Aug 31, 2026.
- Share count: 3.57M shares outstanding (Aug 13, 2026), +74.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CVKD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.99 | 1.12 | 0.96 | 1.09 | 169.78K |
| Oct 15, 2026 | 0.99 | 1.03 | 0.96 | 0.97 | 104.20K |
| Oct 14, 2026 | 0.93 | 1.10 | 0.92 | 1.02 | 344.30K |
| Oct 13, 2026 | 0.89 | 1.06 | 0.87 | 1.00 | 376.40K |
| Oct 12, 2026 | 0.92 | 0.92 | 0.82 | 0.87 | 111.40K |
| Oct 9, 2026 | 0.97 | 0.97 | 0.90 | 0.91 | 82.40K |
| Oct 8, 2026 | 0.99 | 0.99 | 0.87 | 0.93 | 311.20K |
| Oct 7, 2026 | 1.01 | 1.07 | 0.92 | 0.97 | 1.78M |
| Oct 6, 2026 | 0.94 | 1.05 | 0.90 | 0.99 | 98.00K |
| Oct 5, 2026 | 0.97 | 1.00 | 0.94 | 0.95 | 63.00K |
| Oct 2, 2026 | 0.98 | 1.00 | 0.85 | 0.94 | 149.60K |
| Oct 1, 2026 | 1.09 | 1.09 | 0.97 | 0.97 | 109.20K |
| Sep 30, 2026 | 1.10 | 1.10 | 1.05 | 1.08 | 21.70K |
| Sep 29, 2026 | 1.10 | 1.13 | 1.08 | 1.09 | 38.20K |
| Sep 28, 2026 | 1.16 | 1.16 | 1.07 | 1.12 | 75.60K |
| Sep 25, 2026 | 1.25 | 1.25 | 1.13 | 1.15 | 224.70K |
| Sep 24, 2026 | 1.31 | 1.36 | 1.19 | 1.20 | 119.00K |
| Sep 23, 2026 | 1.12 | 1.35 | 1.06 | 1.32 | 269.00K |
| Sep 22, 2026 | 1.11 | 1.14 | 1.06 | 1.12 | 73.50K |
| Sep 21, 2026 | 1.07 | 1.11 | 1.06 | 1.09 | 66.80K |
About Cadrenal Therapeutics
Cadrenal Therapeutics (CVKD) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PONTE VEDRA, FL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1937993.
CVKD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Lee Scott Golden | Director | Dec 3, 2025 |
| Quang X Pham | Chairman and CEO | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Quang X Pham | Chairman and CEO | Jul 1, 2026 |
| Matthew K Szot | Chief Financial Officer | Dec 31, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | Quang X Pham | Sale | 7,400 | $3.03 |
| Jun 29, 2026 | Quang X Pham | Sale | 7,400 | $3.03 |
| Jun 29, 2026 | Quang X Pham | Sale | 7,400 | $3.03 |
| Jun 29, 2026 | Quang X Pham | Sale | 7,400 | $3.03 |
| Jun 26, 2026 | Quang X Pham | Sale | 9,029 | $3.05 |
| Jun 26, 2026 | Quang X Pham | Sale | 9,029 | $3.05 |
| Jun 26, 2026 | Quang X Pham | Sale | 9,029 | $3.05 |
| Jun 26, 2026 | Quang X Pham | Sale | 9,029 | $3.05 |
| Jun 25, 2026 | Quang X Pham | Sale | 2,127 | $3.00 |
| Jun 25, 2026 | Quang X Pham | Sale | 2,127 | $3.00 |
| Jun 25, 2026 | Quang X Pham | Sale | 2,127 | $3.00 |
| Jun 25, 2026 | Quang X Pham | Sale | 2,127 | $3.00 |
| Jun 23, 2026 | Quang X Pham | Sale | 2,277 | $3.20 |
| Jun 23, 2026 | Quang X Pham | Sale | 2,277 | $3.20 |
| Jun 23, 2026 | Quang X Pham | Sale | 2,277 | $3.20 |
CVKD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-13.24M | -6.64 | $-12.60M |
| Dec 31, 2024 | — | $-10.65M | -8.73 | $-7.36M |
| Dec 31, 2023 | — | $-8.36M | -9.29 | $-3.53M |
| Dec 31, 2022 | — | $-6.71M | -0.85 | $-1.20M |
Latest balance sheet: total assets $5.59M, total liabilities $1.50M, cash $2.39M (as of Jun 30, 2026).
CVKD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $1.86 |
| May 7, 2026 | 8-K Item 2.02 (results) | $6.02 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $5.12 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $11.76 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $10.94 |
| May 8, 2025 | 8-K Item 2.02 (results) | $15.50 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $17.45 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $16.29 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
| Aug 10, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CVKD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.